Medication Handling SWMS (Hazardous Drugs)
Ordering, receipt, storage, preparation, dispensing, administration, and waste handling of hazardous drugs (cytotoxics, monoclonal antibodies, hormonal agents). Covers Class II biosafety cabinet use, closed-system transfer devices, double-glove PPE, spill kit response, and bodily-fluid exposure from 48-hour post-treatment patients.
SWMS variants reference your state’s WHS legislation. Instant download after payment.
Medication handling involving hazardous drugs — including cytotoxic agents, monoclonal antibodies, hormonal preparations, and other antineoplastic medicines — presents one of the most complex occupational exposure profiles in Australian healthcare. Workers across oncology pharmacies, day infusion units, inpatient wards, veterinary oncology services, and aged care facilities are exposed through aerosol inhalation, dermal absorption, accidental injection, ingestion via contaminated surfaces, and contact with bodily fluids of treated patients for up to 7 days post-administration. The Safe Work Australia Guide for Handling Cytotoxic Drugs and Related Waste (2019) and the eviQ hazardous medicines framework set the contemporary benchmark for safe practice, supported by AS 2243.5 (laboratory fume cupboards), AS 1668.2 (mechanical ventilation), and ISO 14644 cleanroom classifications for compounding environments.
Under the model Work Health and Safety Regulation 2025, hazardous drugs are classified as hazardous chemicals under Part 7.1, triggering duties around manifest documentation, register and SDS access, health monitoring, atmospheric monitoring, induction and training, and the hierarchy of controls under regulation 36. Section 19 of the WHS Act 2011 imposes the primary duty on the PCBU to eliminate risk so far as is reasonably practicable, and where elimination is not possible, to minimise risk through substitution, isolation and engineering controls before relying on PPE.
This SWMS is legally required because hazardous drug handling is high-consequence work involving Schedule 4 and Schedule 8 poisons regulated under each state's Poisons and Therapeutic Goods legislation, with documented carcinogenic, mutagenic and reproductive toxicity (CMR) endpoints. A documented SWMS demonstrates discharge of consultation duties under section 47 of the WHS Act, supports health monitoring obligations under regulation 368, and provides the auditable evidence trail required during pharmacy board inspections and SafeWork regulator audits.
Hazards identified
14 hazards covered, sorted by priority.
Inhalation of carcinogenic particulate causing long-term cancer risk, reproductive harm and acute respiratory irritation
Direct intravenous self-injection of cytotoxic agent causing tissue necrosis, systemic toxicity and bloodborne virus exposure
Chronic low-dose exposure with cumulative carcinogenic, teratogenic and reproductive effects
Wide-area contamination, exposure of bystanders and inadequate decontamination if spill kit unavailable
Secondary exposure of nursing, cleaning and laundry staff to active drug metabolites
Loss of containment, operator exposure and contamination of compounded product
Undetected dermal exposure where gloves are not changed at 30-minute intervals or after contamination
Downstream exposure of orderlies, cleaners and waste contractors; breach of EPA waste tracking obligations
Foetal harm, miscarriage, congenital malformation and reproductive toxicity
Musculoskeletal injury and increased risk of dropping product causing spillage
Falls resulting in fractures and secondary exposure if cytotoxic product is involved
Loss of closed-system integrity, aerosol release and microbial contamination of patient dose
Build-up of volatile drug residues and worker exposure outside the controlled pharmacy environment
Skipped PPE donning steps, missed double-checks and increased exposure incidents
Control measures
Hierarchy-of-controls order: elimination → substitution → isolation → engineering → administrative → PPE.
- 1Compound all hazardous drugs within a Class II Type B2 biosafety cabinet or isolator located in a negative-pressure ISO Class 5 cleanroom, certified annually against AS 2252.2 and ISO 14644-1, with airflow verification logged before each shift
- 2Use closed-system transfer devices (CSTDs) compliant with NIOSH containment performance protocol for all reconstitution, transfer and administration steps to eliminate aerosol release at every connection point
- 3Mandate double-gloving with chemotherapy-rated nitrile gloves tested to ASTM D6978, changed every 30 minutes or immediately upon contamination, with the outer glove donned over the gown cuff
- 4Provide a full PPE ensemble of disposable low-permeability gown with closed front and elasticated cuffs, P2/N95 fit-tested respirator for spill response, eye protection and overshoes, donned and doffed in a defined sequence in the anteroom
- 5Maintain commercially supplied cytotoxic spill kits at every preparation, transport and administration location, with monthly inventory checks and documented spill response drills every 6 months
- 6Implement a hazardous medicines register and current SDS access in line with WHS Regulation 2025 regulations 344-346, with manifest quantities reported to the regulator where thresholds are exceeded
- 7Apply alternative duties policy removing pregnant, breastfeeding and fertility-planning workers from hazardous drug handling, supported by a confidential self-declaration process and re-allocation procedure
- 8Conduct baseline and ongoing health monitoring under WHS Regulation 2025 regulation 368 by a registered medical practitioner experienced in cytotoxic exposure, including biological monitoring where indicated by eviQ guidance
- 9Label all cytotoxic waste with the purple cytotoxic trefoil symbol per AS 3816 and segregate into rigid UN-approved containers, tracked via EPA waste consignment notes to a licensed treatment facility
- 10Apply universal cytotoxic precautions for 7 days post-administration including double-flushing toilets, dedicated linen handling with cytotoxic-rated bags, and disposable PPE for all bodily fluid contact
- 11Require two-person independent verification of dose calculation, compounding and administration with electronic prescribing system records, in line with eviQ and Australian Commission on Safety and Quality in Health Care standards
- 12Deliver competency-based induction and annual refresher training including aseptic technique validation, spill response simulation and documented sign-off held in worker training records for 30 years
- 13Restrict access to compounding and administration areas via swipe-card to authorised, trained personnel only, with visitor and student access prohibited during active compounding
Applicable Codes of Practice
Primary national guidance on risk assessment, engineering controls, PPE, spill response and waste management for cytotoxic and hazardous medicine handling
Approved code under section 274 of the WHS Act covering SDS access, register and manifest, labelling, induction, atmospheric and health monitoring obligations
Sets the hierarchy of controls framework and consultation requirements applied throughout this SWMS
Governs selection, fit-testing, maintenance and worker training for chemotherapy gloves, gowns and respiratory protection
Specifies design, performance and certification requirements for the primary engineering control used in cytotoxic compounding
Defines facility design, personal protection and emergency response standards for cytotoxic handling
Mandates segregation, labelling, packaging and tracking requirements for cytotoxic and pharmaceutical waste streams
National clinical reference for safe handling, administration and waste protocols for antineoplastic and hazardous medicines
High-Risk Construction Work triggered
Cytotoxic, hormonal and antineoplastic agents are classified as hazardous chemicals under WHS Regulation 2025 Part 7.1 with CMR (carcinogenic, mutagenic, reproductive toxicant) hazard categories. Where pharmacy holdings exceed Schedule 11 manifest quantities, the PCBU must maintain a manifest, notify the regulator, and apply the full suite of hazardous chemical duties including SDS, register, labelling, induction, health monitoring, and emergency planning.
Failure to document a SWMS for handling of manifest-quantity hazardous chemicals exposes the PCBU to category 1 and 2 offences under sections 31 and 32 of the WHS Act 2011, with maximum penalties of $3.99 million for a body corporate and $799,000 plus 5 years imprisonment for an officer where reckless conduct causes exposure. Health monitoring failures attract additional penalties under WHS Regulation 2025 regulation 368, and supply of incorrectly handled Schedule 4/8 medicines breaches state Poisons legislation with separate disciplinary action by AHPRA and the Pharmacy Board of Australia.
Who this is for
- →Hospital and compounding pharmacists preparing cytotoxic and hazardous medicine doses
- →Pharmacy technicians and aseptic compounding assistants working in oncology pharmacy cleanrooms
- →Oncology, haematology and palliative care nurses administering chemotherapy and monoclonal antibody infusions
- →Cleaning, orderly and laundry staff managing patient bodily fluids and contaminated linen post-treatment
- →Veterinary practices administering chemotherapy to companion animals
- →Clinical waste contractors transporting and treating cytotoxic waste streams
- →Pharmacy and nursing managers responsible for WHS consultation, training and health monitoring programs
What you receive
- ✓Fully editable Microsoft Word (DOCX) SWMS template pre-populated for hazardous drug handling and ready for site-specific customisation
- ✓State-specific legislation schedule mapped to NSW, VIC, QLD, WA, SA, TAS, ACT and NT WHS and Poisons frameworks
- ✓Comprehensive hazard register covering all 14 identified hazards with risk-rating matrix and residual risk scoring
- ✓Worker sign-on register meeting consultation evidence requirements under section 47 of the WHS Act 2011
- ✓Cytotoxic spill response flowchart aligned to Safe Work Australia 2019 Guide
- ✓PPE donning and doffing sequence checklist for the anteroom
- ✓Health monitoring schedule template referencing eviQ and registered medical practitioner requirements
- ✓Pre-start verification checklist for biosafety cabinet airflow, certification and CSTD inventory
Worked example
Priya is a Grade 2 oncology pharmacist at a metropolitan day infusion centre preparing a 1,400 mg cyclophosphamide dose for a breast cancer patient. Before commencing, she reviews this SWMS with the technician, checks the Class II Type B2 biosafety cabinet airflow log and the latest annual certification certificate against AS 2252.2, confirms the negative-pressure differential on the cleanroom Magnehelic gauge, and signs the daily pre-start register. She dons the PPE ensemble in the documented sequence in the anteroom — inner nitrile gloves, fluid-resistant chemotherapy gown, P2 respirator (kept on hand for spill response), eye protection, then outer ASTM D6978-tested gloves over the gown cuff. During reconstitution Priya uses a NIOSH-compliant CSTD vial adaptor and syringe connector, eliminating aerosol release at each connection. Twenty-five minutes into the session she changes both pairs of gloves per the SWMS schedule. The compounded dose is double-checked by a second pharmacist, labelled with the purple cytotoxic trefoil, sealed in a leak-proof transport container, and hand-delivered to the chairside nurse who signs the chain-of-custody record. After administration the empty bag, line and CSTD components go directly into a rigid UN-approved cytotoxic waste bin. Housekeeping is briefed that the patient remains under universal cytotoxic precautions for 7 days, and the toilet signage is activated. Every step is auditable against this SWMS, demonstrating discharge of the PCBU's primary duty under section 19 of the WHS Act 2011.
Related legislation
- Work Health and Safety Act 2011 (model)
- Work Health and Safety Regulation 2025 — Part 7.1 Hazardous Chemicals
- Work Health and Safety Regulation 2025 — Part 3.1 Managing Risks to Health and Safety
- Poisons and Therapeutic Goods Act 1966 (NSW) and equivalent state Drugs, Poisons and Controlled Substances legislation
- Therapeutic Goods Act 1989 (Cth)
- Protection of the Environment Operations Act 1997 (NSW) and equivalent state EPA waste legislation
- Health Practitioner Regulation National Law and Pharmacy Board of Australia Professional Practice Standards
- National Safety and Quality Health Service (NSQHS) Standards — Standard 4 Medication Safety
Frequently asked questions
Is a SWMS legally required for cytotoxic drug handling even though it is not listed as one of the 18 high-risk construction work categories?
Yes. While the 18 HRCW categories under WHS Regulation 2025 regulation 291 specifically apply to construction work, healthcare PCBUs handling hazardous chemicals are independently required under Part 7.1 to assess risk, document control measures, train workers, and maintain health monitoring records. A SWMS is the most effective single document to discharge these obligations, evidence consultation under section 47 of the WHS Act, and satisfy SafeWork regulator and pharmacy board auditors.
How often must this SWMS be reviewed?
The SWMS must be reviewed whenever the work changes, after any incident or near-miss, when new hazardous medicines are introduced to the formulary, when the biosafety cabinet is recertified, or at minimum every 12 months. Review must be done in consultation with affected workers and HSRs under sections 47-49 of the WHS Act 2011, with the review date and signatories recorded on the document control page.
Does this SWMS cover monoclonal antibodies and hormonal agents, or only traditional cytotoxics?
Yes. The scope explicitly covers all hazardous medicines defined under the eviQ hazardous medicines framework and the NIOSH list, including cytotoxic chemotherapy, monoclonal antibodies (e.g. trastuzumab, rituximab), hormonal antineoplastics (e.g. tamoxifen, bicalutamide), and antiviral, immunosuppressant and teratogenic agents where local risk assessment classifies them as hazardous.
What health monitoring is required for workers handling these drugs?
Under WHS Regulation 2025 regulation 368, health monitoring must be provided where workers are at significant risk of adverse health effects from exposure to a hazardous chemical. For cytotoxics this includes baseline and periodic medical assessment by a registered medical practitioner experienced in occupational toxicology, with biological monitoring (e.g. urinary platinum, cyclophosphamide) considered where eviQ or the SDS indicates. Records must be retained for 30 years after the last entry.
How should we manage workers who declare pregnancy or are trying to conceive?
The PCBU must offer alternative duties that remove the worker from any handling, administration or bodily fluid contact involving hazardous drugs. This is supported by the Safe Work Australia 2019 Guide and reflects the carcinogenic, mutagenic and reproductive toxicant (CMR) classification of these agents. A confidential self-declaration process should be in place, and the alternative duties policy referenced in this SWMS provides a template procedure.
Is this SWMS suitable for veterinary oncology and aged care settings?
Yes. The hazard profile and control framework apply equally wherever hazardous medicines are handled — including veterinary chemotherapy, residential aged care administration of oral cytotoxics and hormonal agents, and home-care nursing. The template includes sections for site-specific customisation of facility, ventilation and waste arrangements to suit non-hospital environments.